A new delivery sytem

to provide solutions for different lung diseases.

Science

 Pulmobiotics will use its technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.

 Top 10 cause of death in 2016 in the World

 More than 1 billion persons suffer from chronic respiratory conditions worldwide, including 235 million people suffering from asthma and more than 200 million people enduring chronic obstructive pulmonary disease (COPD) which is moderate to severe in 65 million. 8.7 million people develop tuberculosis annually and more than 50 million people struggle with occupational lung diseases [1].

Respiratory diseases are also among the leading causes of death worldwide, with 3.5 million deaths being attributed to lower respiratory diseases, 3.3 million to COPD and 1.4 million to tracheal, bronchial or lung cancer [2].

 Ventilator associated pneumonia

 Our first live biotherapeutics product is for the treatment of Ventilator-associated pneumonia (VAP), a type of pneumonia that develops 48–72 hours following endotracheal intubation of patients required assisted ventilation [3-5].
 

  • Around 400,000 VAP cases/year in Europe and USA VAP mortality 3 - 17%

  • Increases intensive care unit (ICU) stay between 4 and 13 days
     

  • Incremental hospitalization costs of 25,000$ - 40,000$ per  diagnosis (USA)
     

  • 50% of all antibiotics administered in ICUs are for treatment  of VAP
     

  • Significant resistance to antibiotics: 8.3% vancomycin, 50% methilin, rising for piperacillin-tazobactam (PTZ), amikacin and imipenem (IPM)

 Our VAP product uses attenuated lung bacteria to deliver therapeutic agents with antibacterial activity in the lung in a controlled, local and continuous manner.
This product has already demonstrated activity in vitro and in animal models.

 Pulmobiotics       |       Platform       |      Respiratory diseases     |      Partners       |       Team        |     Contact

 [1] Forum of International Respiratory Societies, Respiratory diseases in the world
[2] World Health Organization, World Health Statistics 2011
[3] Chastre, Ventilator-associated pneumonia. Am J Respir Crit Care Med, 2002.
[4] Kalanuria, Ventilator-associated pneumonia in the ICU. Crit Care, 2014.
[5] Fernandez-Barat, Biofilms in ventilator-associated pneumonia. Future Microbiol, 2016

 References

Pioneering live biotherapeutics

in the respiratory tract.

Twitter_pulmobiotics.gif
icona-linkedin.png

Follow us

Pulmobiotics - All rights reserved © 2020